Sinusoidal Obstruction Syndrome (SOS) in Multiple Myeloma with Renal Failure
| Autor: | John F. Reinus, Amit Verma, Noah Kornblum, Yang Shi, Olga Derman, Urvi A Shah, Sengottuvel Viswanathan, Ioannis Mantzaris, Beamon Agarwal, Ira Braunschweig, Murali Janakiram, Aditi Shastri |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Melphalan
Drug medicine.medical_specialty Cyclophosphamide media_common.quotation_subject Case Report Defibrotide lcsh:RC254-282 03 medical and health sciences 0302 clinical medicine medicine Intensive care medicine Multiple myeloma media_common business.industry lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Transplantation Oncology 030220 oncology & carcinogenesis bacteria Complication business Busulfan 030215 immunology medicine.drug |
| Zdroj: | Case Reports in Oncological Medicine, Vol 2018 (2018) Case Reports in Oncological Medicine |
| ISSN: | 2090-6714 2090-6706 |
| Popis: | SOS is a rare complication of stem cell transplantation and has significant morbidity and mortality. We present three cases of SOS and highlight underlying risk factors for its development, such as impaired clearance of alkylating agents (especially melphalan) in patients with renal failure and prolonged infection. Although, melphalan and cyclophosphamide cause SOS less commonly than alkylating agents such as busulfan, physicians must use caution when administering these drugs to patients with underlying comorbidities such as renal failure that may increase the likelihood of development of SOS. This is due to unpredictable pharmacokinetics in patients with renal failure and therefore close drug monitoring is required. With the recent FDA approval of defibrotide in 2016, outcomes of SOS have improved and physician awareness is important for prompt diagnosis and treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |